TF
TEVA icon

Tompkins Financial’s Teva Pharmaceuticals TEVA Stock Holding History

Tompkins Financial’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,050
Closed -$17.1K – 618
2024
Q2 		$17.1K Hold
1,050
– – ﹤0.01% 449
2024
Q1 		$14.8K Hold
1,050
– – ﹤0.01% 466
2023
Q4 		$11K Buy
+1,050
New +$9.8K ﹤0.01% 484
2014
Q4 		– Sell
-2,335
Closed -$126K – 491
2014
Q3 		$126K Hold
2,335
– – 0.03% 178
2014
Q2 		$122K Hold
2,335
– – 0.03% 189
2014
Q1 		$123K Sell
2,335
-445
-16% -$20.6K 0.03% 181
2013
Q4 		$111K Sell
2,780
-706
-20% -$27.8K 0.03% 187
2013
Q3 		$132K Buy
3,486
+56
+2% +$2.18K 0.04% 169
2013
Q2 		$134K Buy
+3,430
New +$134K 0.04% 166

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Tompkins Financial's TEVA Position: Q3 2024 in Review

Tompkins Financial sold out of Teva Pharmaceuticals (TEVA) in Q3 2024, closing a stake of 1,050 shares — an estimated $17.1K sold.

Tompkins Financial first reported a position in TEVA in Q2 2013 and held it in 9 quarters. The position peaked at $134K in Q2 2013. 542 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • Tompkins Financial reported no remaining Teva Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Tompkins Financial sold 1,050 Teva Pharmaceuticals shares in Q3 2024, an estimated $17.1K.
  • Tompkins Financial first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 9 quarters.
  • Tompkins Financial's Teva Pharmaceuticals position peaked at $134K in Q2 2013.
  • 542 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Tompkins Financial's 13F filing for Q3 2024, filed 1 Nov 2024.